Attentin (dexamphetamine) is a prescription drug, 5 mg, 10 mg and 20 mg tablets.
Indication: Dexamphetamine is intended for children and adolescents aged 6 to 17 as part of a comprehensive
treatment program for ADHD (Attention Deficit Hyperactivity Disorder) when responding to earlier
treatment with methylphenidate is considered to be clinically inadequate. Treatment should be under supervision
by specialist on behavioral disorders in children and / or young people.
Contraindications: Hypersensitivity to the active substance or to any excipient, glaucoma, pheochromocytoma, symptomatic cardiovascular disease, structural heart disease and / or moderate or severe hypertension, heart failure, arterial narrowing, angina, hemodynamically significant congenital heart disease, cardiomyopathies, myocardial infarction, cardiac myocardial infarction, potentially life-threatening arrhythmias, and cardiac myocardial infarction (diseases caused by a dysfunction of ion channels) advanced arteriosclerosis, concomitant use of monoamine oxidase inhibitors (MAO inhibitors) or within 14 days of treatment with MAO inhibitors, hyperthyroidism or thyroid toxicosis, severe depression, anorexia nervosa / anorectic disorders, hyperexcitability, suicidal thoughts, psychotic disorders symptoms, severe and episodic (type I) bipolar (affective) disease (not well controlled), schizophrenia, psychopathic / borderline personality disorder, tourette's syndrome or similar dystonias, cerebrovascular disease (cerebral aneurysm, vascular disorders including vasculitis or stroke), porphyria, previous drug or alcohol abuse. Very common side effects: decreased appetite, decreased weight gain and weight loss during prolonged use in children. Common side effects: arrhythmia, palpitations, tachycardia, abdominal pain and seizures, nausea, vomiting, dry mouth, changes in blood pressure and heart rate (usually elevations), arthralgia, vertigo, dyskinesia, headache, hyperactivity, abnormal behavior, aggression, excitation, anorexia, anxiety, anxiety, anxiety, anxiety, anxiety, depression, irritability. For further information see www.fass.se.
Swedish representative Evolan Pharma AB, Box 120, 182 20 Danderyd. Tel. +46 8 544 960 30 www.evolan.se.
An extensive treatment program usually includes psychological, educational and social measures. Diagnosis should be made according to the criteria in the DSM-5 or the guidelines in ICD-10 and should be based on a comprehensive multidisciplinary evaluation of the patient.
Dexamfetamine is indicated as part of a comprehensive treatment program for Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents aged 6 to 17 years when response to previous methylphenidate treatment is considered clinically inadequate. A comprehensive treatment program typically includes psychological, educational and social measures.

Diagnosis should be made according to DSM-5 criteria or the guidelines in ICD-10 and should be based on a comprehensive multidisciplinary evaluation of the patient.

Invicorp is an injectable drug available on prescription. Invicorp 25 micrograms / 2 mg: 1 dose (ampoule 0.35 ml) contains 25 micrograms of aviptadil (vasoactive intestinal polypeptide) and 2 mg of phentolamine mesilate. Invicorp is available in packs of 2 and 5 ampoules. Therapeutic indications: symptomatic treatment of erectile dysfunction with neurogenic, vascular, psychogenic or mixed etiology in adult men. Contraindications: Men for whom sexual activity is not suitable or is contraindicated due to organic disease. Treatment with anticoagulants such as heparin and warfarin, including oral anticoagulants, such as dabigartan, rivaroxaban or apixaban. Men with any of the following conditions should not be treated with Invicorp: conditions that can predispose to priapism such as sickle cell anemia, multiple myeloma or leukemia. Hypersensitivity to the active substances or to any of the excipients.
Side effects: common side effects are flushing and bruising. Uncommon side effects include dizziness, headache, palpitations, tachycardia and hematoma. Rare side effects are priapism, penile nodules / fibrosis (after multiple injections) and pain after injection. Very rare side effects are myocardial infarction and angina pectoris. For further information, see the Summary of Product Characteristics or www.fass.se.
Evolan Pharma AB, tel. 08 - 544 960 30

Invicorp should be administered by direct intracavernous injection. The first injections of Invicorp must be given by healthcare professionals and after proper training, Invicorp can be injected into the home. Patients should be monitored regularly (eg, every three months), especially during the initial period of self-injection.
www.fass.se/Invicorp

Medikinet® (methylphenidate) is a prescription drug within the drug benefit. Tablets 5 mg, 10 mg and 20 mg and modified release capsules 5 mg,
10 mg, 20 mg, 30 mg, 40 mg, 50 mg and 60 mg. Indications: Medikinet® is indicated as part of the overall treatment program for ADHD (Attention Deficit
Hyperactivity Disorder) in children over 6 years of age, when only supportive measures have been shown to be inadequate. Treatment should be under the supervision of a physician specialized in the treatment
behavioral disorders in children.
It may be appropriate to continue the treatment with Medikinet into adulthood if symptoms persist and if the patient has benefited from the treatment.
Contraindications: Do not use in children with anxiety, symptoms of severe depression, psychotic symptoms, psychopathological personality changes,
tense, troubled, tics, Tourette's syndrome, cardiovascular disease, glaucoma, hyperthyroidism, thyroid toxicosis, hypersensitivity to methylphenidate, etc.
Side effects: Nervousness, insomnia, loss of appetite. For further information see product summary or www.fass.se. Evolan Pharma AB, tel. 08-544 960 30.
Treatment must be under
the supervision of a specialist in childhood behavioral disorders. Diagnosis
should be made according to the criteria of the DSM-IV or the guidelines in
ICD-10 and will be based on a complete history and evaluation of the patient.

Indications: Melatan contains the active substance melatonin and is intended for short-term treatment of jet lag in adults over 18 years. The drug is recommended for adults over the age of 18 who fly over at least 5 time zones, especially to the east, and especially if they have experienced jet lag symptoms during previous trips. If needed, it can also be used by travelers passing 2–4 time zones.
Warnings: The timing of the intake of melatonin is important. Melatan should be used as directions describes. Melatonin can cause drowsiness. The drug should therefore be used with caution if the effects of drowsiness are likely to pose safety risks.
There are no clinical data on the use of melatonin in people with autoimmune disorders. Therefore, Melatan is not recommended for patients with autoimmune disorders.
Hepatic and renal impairment:
There is only limited experience/data regarding the safety and efficacy of melatonin use in patients with hepatic or renal impairment. Melatan is not recommended for patients with hepatic impairment or severe renal impairment.
Read the package leaflet carefully before use. Always take this medicine as your doctor prescribes or the pharmacist has told you. Ask your doctor or pharmacist if you are unsure.
Drug benefit and price: Melatan is not included in the benefit system. For current prices, see Fass.se. Product Summary updated 2019-09-06. For more information visit www.fass.se
Evolan Pharma AB, Box 120, SE-182 12 Danderyd, Sweden. www.evolan.se